Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841165 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL4095856 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL1807882 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2MAOAMAOB | |
| SCHEMBL30844218 | 0.85 | NOS1 (0.33) | NOS1NOS3NOS2MAOAMAOB | |
| SCHEMBL569252 | 0.85 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL1934270 | 0.83 | CYP2D6 (0.41) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL2603689 | 0.83 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL375959 | 0.83 | LTA4H (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL18758702 | 0.83 | CYP2D6 (0.41) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL330114 | 0.83 | LTA4H (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109535035-A | A kind of preparation method of the N- benzyloxycarbonyl group -3- amino-alanine tert-butyl ester | 吉尔生化（上海）有限公司 | 2019-03-29 | — | — | CN | claimed |
| JP-2005507020-A | — | — | 2005-03-10 | — | — | JP | claimed |
| EP-1440123-A1 | THERMOPLASTIC SILICONE ELASTOMERS FROM COMPATIBILIZED POLYAMIDE RESINS | Dow Corning Corporation (US) | 2004-07-28 | — | — | EP | claimed |
| WO-2003035759-A1 | THERMOPLASTIC SILICONE ELASTOMERS FROM COMPATIBILIZED POLYAMIDE RESINS | DOW CORNING CORPORATION (US) | 2003-05-01 | — | — | WO | claimed |
| EP-0719301-B1 | RECYCLING OF CARPET SCRAP | MASLAND IND INC (US) | 2001-06-20 | — | — | EP | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
| US-4426324-A | Immunopotentiating peptides | HOFFMANN-LA ROCHE INC. (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0026464-A2 | Peptides, their production, their use, and pharmaceutical preparations | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-08 | — | — | EP | disclosed |
| US-4198517-A | Histidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1980-04-15 | — | — | US | disclosed |
| US-4154736-A | Indolylalkylene amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4128721-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4127729-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4091024-A | Pyrrolidine and piperidine-2-carboxylic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | NOS1 2821/4885NOS3 1674/4885NOS2 2376/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NOS1 3216/4885NOS3 2625/4885NOS2 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.